NCT04739072View on ClinicalTrials.gov

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Colorectal AdenocarcinomaStage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v6Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

OTHER

Electronic Health Record Review

Review of medical records

Trial Locations (10)

32207

TERMINATED

Baptist- MD Anderson Cancer Center, Jacksonville

75390

TERMINATED

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

76508

TERMINATED

Baylor Scott & White Research Institute, Temple

77030

TERMINATED

Houston Methodist Cancer Center, Houston

RECRUITING

M D Anderson Cancer Center, Houston

78229

TERMINATED

UT Health San Antonio MD Anderson Cancer Center, San Antonio

83712

TERMINATED

St. Luke's Cancer Institute, Boise

85234

TERMINATED

Banner - MD Anderson Cancer Center, Gilbert

96813

TERMINATED

The Queen's Medical Center, Honolulu

08103

TERMINATED

Cooper Hospital UNIV MED CTR., Camden

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER